Dare Bioscience (DARE) Shares Up 5.5%

Dare Bioscience (NASDAQ:DARE)’s share price shot up 5.5% during mid-day trading on Thursday . The company traded as high as $1.22 and last traded at $1.16. 760,900 shares traded hands during mid-day trading, a decline of 19% from the average session volume of 937,513 shares. The stock had previously closed at $1.10.

A number of brokerages recently issued reports on DARE. Roth Capital began coverage on shares of Dare Bioscience in a research report on Wednesday. They issued a “buy” rating and a $6.00 target price for the company. ValuEngine upgraded shares of Dare Bioscience from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd.

Dare Bioscience (NASDAQ:DARE) last announced its earnings results on Monday, April 2nd. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter.

An institutional investor recently bought a new position in Dare Bioscience stock. CVI Holdings LLC bought a new stake in Dare Bioscience (NASDAQ:DARE) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 471,661 shares of the biotechnology company’s stock, valued at approximately $395,000. Dare Bioscience makes up about 0.5% of CVI Holdings LLC’s holdings, making the stock its 22nd largest holding. CVI Holdings LLC owned 4.13% of Dare Bioscience at the end of the most recent quarter. 4.22% of the stock is currently owned by institutional investors.

Dare Bioscience Company Profile

Daré Bioscience, Inc, a clinical-stage biopharmaceutical company, focuses on developing and marketing women's reproductive health products in the United States. The company intends to develop therapies in the areas of contraception, vaginal health, sexual health, and fertility. Its product candidates include Ovaprene, a non-hormonal monthly contraceptive; and SST-6007, a topical sildenafil cream for female sexual arousal disorder.

Receive News & Ratings for Dare Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dare Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit